Arrowhead Research Corporation vs Eli Lilly & Co.
ARWR vs LLY — side-by-side comparison from reported financials. ARWR leads 3, LLY leads 7 of 10 comparable metrics.
Arrowhead Research Corporation
ARWR · Healthcare
$62.75+3.31%Solid
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | ARWR | LLY |
|---|---|---|
| Price | $62.75 | $1 177.20 |
| Market cap | $8.86B | $1.05T |
| Revenue (TTM) | $669M | $79.7B |
| Revenue growth | +50.5% | +31.7% |
| Net margin | -47.8% | 33.5% |
| Free cash flow | -$75.1M | $18.2B |
| Net cash (debt) | $478M | ($35.2B) |
| 1-year price return | +74.0% | +37.6% |
| P/E | — | 41.6 |
| P/E vs own history (cheap-side %) | 85% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | -61% | 93% |
| Altman Z-score | 2.52 | 7.10 |
| CV checks passed | 5 of 9 | 11 of 9 |
| Employees | 711 | 50,000 |
Full résumé-style profiles: ARWR CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.